Adagene Inc. (ADAG) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ADAG scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 3/20 (ROIC -35%; FCF yield -8.85%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 0.2; Piotroski F 5/9; Debt/Equity 0.03).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, both scoring 3 of 20. The negative ROIC and negative FCF yield indicate the business is currently consuming capital rather than generating it, per the Roarable RQD rating and market data. The Altman Z-Score of 0.2 sits in the distress territory of the source's framing, and the Piotroski F-Score of 5/9 signals mixed rather than strong fundamental health. The low Debt/Equity of 0.03 is the most favorable forensic datapoint, indicating limited leverage, though the cash-burn trend is the central concern. Upside drivers would need to come from clinical or partnership catalysts rather than current earnings. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data.

Per the SEC financials, operating losses persisted across all three reported periods, with FY 2025 operating income at $-21.4M against revenue of $7.7M. Market data shows operating and net margins of -60%, a gross margin of 0%, and ROIC of -35%. The Altman Z-Score of 0.2 and Piotroski F-Score of 5/9 are reported in the Roarable RQD rating, alongside Debt/Equity of 0.03. Cash declined from $85.2M in FY 2024 to $74.5M in FY 2025 while debt rose from $0.4M to $1.1M.

Per the recent news wire, several items reference ADAG, all flagged YELLOW with impact label MARKET WIRE. Headlines include a Yahoo! Finance Canada market report, a StockInvest.us forecast, a TradingView estimates page, and a Stock Titan item reporting that the first patient has received two drugs together in a colorectal cancer study. A separate item reports HC Wainwright & Co. reiterating a Buy rating with a $7 price target. A further item reports shares slipping to $2.76 while testing the lower end of a recent range. The news feed contains no proprietary risk signals. Note that one item's summary field references an unrelated domain rather than a substantive description, and should be treated as unverified. The Butterfly supply-chain graph reports no proprietary signals.

• What is the company's cash runway given FY 2025 FCF of $-15.7M against a reported cash balance of $74.5M?
• What specific clinical programs, partnerships, or milestones drive revenue, and what is their timing?
• What explains the rise in debt from $0.4M to $1.1M between FY 2024 and FY 2025?
• Why are P/E, EPS, and EV/EBITDA unavailable, and what is the company's valuation on forward cash flow?
• What institutional or insider positioning exists, given that holder and analyst datasets are empty?